Alvotech, Kashiv Biosciences, and Advanz Pharma Announce Positive Results from Efficacy Study of AVT23, a Biosimilar to Xolair®
25/6 10:10
Alvotech, Kashiv, and Advanz announce successful efficacy study results for AVT23, a proposed biosimilar to Xolair® for CSU treatment....